NCT03183622View on ClinicalTrials.gov

A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-BI-101 Clinical Trial

CompletedOBSERVATIONAL
Enrollment

5

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

July 31, 2017

Study Completion Date

December 31, 2017

Conditions
Burn
Interventions
BIOLOGICAL

ALLO-ASC-DFU

"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.~This tudy is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"

Trial Locations (1)

Unknown

Hallym university Medical Center, Seoul

All Listed Sponsors
lead

Anterogen Co., Ltd.

INDUSTRY

NCT03183622 - A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-BI-101 Clinical Trial | Biotech Hunter | Biotech Hunter